Jubilant Pharmova

Jubilant Pharmova receives 4 observations from USFDA after Pre-Approval Inspection at Roorkee facility

Jubilant Pharmova shares surge 4% as Q4 revenue jumps 9.67% YoY to Rs 1,915.8 crore

Jubilant Pharmova Q3 FY25 results: Revenue up 9% YoY to Rs 1822 crore, Net profit surges 52% YoY

Jubilant Pharmova subsidiary Jubilant Biosys acquires 80% stake in JASMIN, expands R&D presence in France

Jubilant Pharmova shares drop 2% after USFDA issues five observations to its US-based unit

Jubilant Pharmova’s US facility inspection results in five USFDA observations

Jubilant Pharmova Q2 Results: Net Profit falls 78.73% QoQ to ₹102.5 crore, Revenue grows marginally to ₹1,742.2 crore

Jubilant Pharmova receives “Official Action Indicated” notice from USFDA for Montreal facility

Jubilant Pharmova shares drop nearly 5% 

Jubilant Pharmova share price surges 24% this week on receiving ‘VAI’ tag for US facility

Jubilant Pharmova shares hit 52-week high, surge over 8% in morning trade

Jubilant Pharmova shares surge 7% on heavy volumes

Jubilant Pharmova shares hit three-year high on acquisition deal

Jubilant Pharmova shares skyrocketed to a three-year high on Monday, reaching Rs 910.25 apiece, after the company announced a significant acquisition deal

Jubilant Pharmova reports 86.4% decline in Q1 net profit, shares dip over 2%

Revenue sees 9% year-on-year rise in Q1FY24 amid challenging times for pharmaceutical company

Jubilant Pharmova Q1 FY-24: Net profit declines by 86% followed by 3% decline in stocks

The company has reported a year-on-year decline in all major financial metrics barring revenue for the recently ended quarter